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Abstract 
Background: Synucleinopathies such as Parkinson’s disease or multiple system atrophy are characterized by Lewy 
bodies in distinct brain areas. These aggregates are mainly formed by α‑synuclein inclusions, a protein crucial for 
synaptic functions in the healthy brain. Transgenic animal models of synucleinopathies are frequently based on 
over‑expression of human wild type or mutated α‑synuclein under the regulatory control of different promoters. A 
promising model is the Line 61 α‑synuclein transgenic mouse that expresses the transgene under control of the Thy‑1 
promoter.
Results: Here, we show an extended characterization of this mouse model over age. To this end, we analyzed 
animals for the progression of human and mouse protein expression levels in different brain areas as well as motor 
and memory deficits. Our results show, that Line 61 mice exhibited an age dependent increase of α‑synuclein protein 
levels in the hippocampus but not the striatum. While murine α‑synuclein was also increased with age, it was lower 
expressed in Line 61 mice than in non‑transgenic littermates. At the age of 9 months animals exhibited increased 
neuroinflammation. Furthermore, we found that Line 61 mice showed severe motor deficits as early as 1 month of 
age as assessed by the wire hanging and nest building tests. At later ages, initial motor deficits were validated with 
the RotaRod, pasta gnawing and beam walk tests. At 8 months of age animals exhibited emotional memory deficits 
as validated with the contextual fear conditioning test.
Conclusion: In summary, our results strengthen and further expand our knowledge about the Line 61 mouse model, 
emphasizing this mouse model as a valuable in vivo tool to test new compounds directed against synucleinopathies.
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Background
The pathology of Parkinson’s disease (PD) is character-
ized by dopaminergic neuron loss in the substantia nigra 
as well as Lewy bodies in distinct brain areas. Lewy bod-
ies are mainly formed by α-synuclein (α-Syn) inclusions 
and are typical for idiopathic as well as familial forms of 
PD [1]. Since α-Syn aggregates are also found in other 
neurodegenerative diseases such as dementia with Lewy 
bodies and multiple system atrophy, all these patholo-
gies are summarized as synucleinopathies. Aggregation 
of α-Syn can be caused by different point mutations [2, 
3] or over-expression of the wild type protein due to 
duplication or triplication of the α-Syn gene SNCA [4–
6]. In order to model synucleinopathies in vivo, different 
mouse models have been developed [7–10]. Here we used 
Line 61 mice that over-express human wildtype α-Syn 
under control of the Thy-1 promoter [8]. Previous experi-
ments with Line 61 mice revealed motor deficits starting 
at an age of 2 months [11]. Their behavioral results match 
well with biochemical and histological results by Rocken-
stein et al. [8] whose initial characterization shows high 
human α-Syn expression throughout the Line 61 mouse 
brain, including the basal ganglia, thalamus and substan-
tia nigra. Additionally, Chesselet and colleagues analyzed 
Line 61 animals for motor and cognitive deficits at the 
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The present study verifies previously published data, 
but additionally shows human and murine α-synuclein 
protein expression over age, neuroinflammation in adult 
animals and documents first motor deficits already at an 
age of 1 month that progress over age. Furthermore, we 




For this study male mice, overexpressing human wild-
type α-Syn under the regulatory control of the Thy-1 
promoter with a C57BL/6xDBA background were used 
(Line 61 [8]). For behavioral tests 1 to 8-month old ani-
mals were used. At least eight animals per group were 
analyzed. All experiments were performed with hemizy-
gous Line 61 mice and corresponding non-transgenic 
littermates.
Animals were housed in individually ventilated cages 
on standardized rodent bedding (Rettenmayer®) in the 
AAALAC accredited animal facility of QPS Austria. The 
room temperature was kept at approximately 21  °C and 
the relative humidity between 40 and 70%. Mice were 
housed under constant light-cycle (12  h light/dark). 
Dried pelleted standard rodent chow (Altromin®) and 
normal tap water were available to the animals ad  libi-
tum. Each individual animal was checked regularly for 
any clinical signs.
Behavioral tests
All behavioral tests were performed during the light 
phase and animals were habituated to the experimental 
room for at least 30 min.
Wire hanging test
The test is also called wire suspension test. A standard 
wire cage lid was used. The mouse was placed on the top 
of the lid. Afterwards, the lid was slightly shaken to cause 
the mouse to grip the wires, and then turned upside 
down. Duct tape placed around the perimeter of the lid 
prevented the mouse from climbing over the edge. The 
latency to fall off the wire lid was measured in seconds. A 
90 s cut-off time was used.
RotaRod
The test assesses motor coordination by placing ani-
mals on a rotating rod (five-lane-Rota Rod; Ugo Basile, 
Italy) that runs at a constant or an accelerating speed. 
The apparatus automatically records the latency to fall 
as well as the speed at fall. All mice were tested on three 
days. After a 180  s training session at a constant speed 
of 2 rpm approximately 1 h before testing on day 1, each 
animal was exposed to the apparatus for a 180 s testing 
session. The initial speed increased from 2 to 20 rpm over 
a period of 180 s in the test sessions. On day 2 and 3, the 
test was performed without training [13].
Pasta gnawing test
This test was developed to study fine motor deficits in 
small rodents and adapted from the pasta handling test 
[14, 15]. Several 1  cm long dry spaghetti noodles were 
provided to each single housed animal. A microphone 
was placed above the cage and as soon as the animal 
started eating, the recording started. Recording time was 
approximately 1 min depending on the intensity of eating 
behavior. Biting was recorded using the Behringer ECM 
8000 microphone with a Steinberg CL1 sound card. The 
number of bites per gnawing episode and the biting fre-
quency were evaluated using Avisoft SAS Lab Pro pro-
gram (Avisoft Bioacoustics, Germany).
Nest building
To test the individual nest building behavior, mice were 
single housed in cages containing wood chip bedding 
and one 5 ×  5  cm square of pressed cotton (‘nestlet’). 
The following morning the nest was assessed according 
to a five-point scale as follows: (1) Nestlet not notice-
ably touched (>90% intact). (2) Nestlet partially torn 
up (50–90% remaining intact). (3) Mostly shredded 
but often not identifiable nest site: <50% of the Nestlet 
remains intact but <90% is within a quarter of the cage 
floor area, i.e. the cotton is not gathered into a nest, 
but spread around the cage. (4) An identifiable, but flat 
nest: >90% of the Nestlet is torn up, the material is gath-
ered into a nest within a quarter of the cage floor area, 
but the nest is flat, with walls higher than mouse body 
height (curled up on its side) on less than 50% of its cir-
cumference. (5) A (near) perfect nest: >90% of the Nest-
let is torn up, the nest is a crater, with walls higher than 
mouse body height on more than 50% of its circumfer-
ence [16].
Beam walk test
Mice were trained and tested to traverse an elevated nar-
row beam, which was brightly illuminated at the start 
and ended in their home cage. Animals were three times 
trained on a square training beam that is slightly wider 
than the square testing beam. At the same day, a square 
beam of 11  mm width and a round beam of 16  mm in 
diameter were used for testing. The testing phase was 
videotaped and analyzed manually. The time to traverse 
the beam and the number of foot slips were analyzed.
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Contextual fear conditioning
The fear conditioning test was conducted in an auto-
mated box (TSE-Systems, Germany). Mice were trained 
and tested on 2 consecutive days. On the training day, 
mice received a foot shock (0.5 mA, 2 s) 5  s after being 
placed into the conditioning chamber. 30  s afterwards 
mice were returned to their home cage. 24 h after train-
ing, mice were tested by being returned to the condition-
ing chamber for 5  min without any shock, and freezing 
behavior was recorded by the automated system and 
evaluated separately for every minute.
Tissue preparation
Tissue was taken from 2-, 3- and 6-month old Line 61 
mice and non-transgenic littermates. Mice were deeply 
anesthetized by Isoflurane (Baxter, Austria) and the 
thorax was opened to excavate the heart. Animals were 
flush-perfused transcardially with 0.9% saline through 
the left ventricle. The hemispheres were divided at mid-
line. One hemisphere was immersion-fixed in 4% para-
formaldehyde in 0.1 M phosphate buffer, pH 7.4, for 2 h 
at room temperature (RT), was then cryoprotected in 
15% sucrose in PBS overnight, embedded in tissue freez-
ing medium (Leica Biosystems, Germany) in cryomolds 
and was snap-frozen in dry ice-cooled liquid isopentane. 
The frozen samples were then stored at −80 °C until sec-
tioning. The other hemisphere was dissected into hip-
pocampus, striatum and rest brain and shock-frozen on 
dry ice and stored at −80 °C for α-Syn determination.
Biochemistry
Protein was extracted in buffer containing 20 mM Tris–
HCl, pH 7.4, 50  mM NaCl, 1% Triton X-100 including 
freshly added 0.2  mM sodium-orthovanadate protease 
inhibitor cocktail (Calbiochem, Germany) and phos-
phatase inhibitor cocktail (Sigma, USA) by using the tis-
sue ruptor (Qiagen, Germany). Lysates were incubated 
for 30 min on ice, followed by centrifugation at 15,000g 
for 60 min at 4 °C. The pellet and supernatant were col-
lected as the Triton X-100-insoluble and soluble frac-
tions, respectively. The Triton X-100-insoluble pellets 
were dissolved in the previously described lysis buffer 
containing 2% SDS. Aliquots of the resulting fractions 
were stored at −80 °C until further analyses.
α-Syn levels in the Triton-X-100 soluble and insoluble 
fraction [17] were determined by using a commercially 
available immunosorbent assay (K151TGD-4; MesoScale 
Discovery, USA) according to the manufacturer’s proto-
col for human α-Syn levels. Evaluation of murine α-Syn 
levels was performed by a self-made MesoScale Discov-
ery plate using the murine specific rabbit anti-murine 
α-synuclein mAb (clone: D37A6, # 4179, Cell Signaling, 
USA). α-Syn levels were evaluated in comparison to a 
recombinant α-synuclein protein (residues 1–140) as 
standard in pg/ng protein provided by the manufacturer.
Histology
Sectioning
Hemispheres were cryosectioned sagittally at 10  µm 
thickness on a Leica CM1950. Sections were mounted 
on polysine slides (Thermo Scientific) and were stored at 
−20 °C.
Immunofluorescence
Double-and triple immunofluorescence experiments 
were performed using the following protocol: Wash cryo-
sections 2 × 5 min in PBS, block 1 h with normal donkey 
serum and 0.2% Triton X-100, wash 2 ×  2  min in PBS, 
incubate 1  h in antibody diluent (Dako) with primary 
antibodies, wash 3 × 5 min, incubate secondary antibod-
ies 30 min in antibody diluents, wash 3 × 5 min in PBS, 
stain nuclei with DAPI, mount with Mowiol. Detailed 
information on all primary antibodies used in this study 
is provided in Table 1.
Secondary antibodies donkey anti-rat, donkey anti-
mouse, donkey anti-rabbit, and donkey anti-goat were 
labelled with AlexaFluor488, AlexaFluor555, or Alex-
aFluor 650 fluorophores (Abcam); all secondary anti-
bodies were highly cross-adsorbed to prevent unspecific 
cross-reactivity. Specificity of secondary antibodies was 
assessed by omitting primary antibodies on parallel sec-
tions. Controls were routinely executed together with 
regular experiments.
Imaging and image analysis
Mosaic images including the entire hippocampus and 
neocortex were captured using a fully motorized Zeiss 
AxioImager Z1 microscope equipped with a Zeiss Axi-
oCam MRm camera and Zeiss AxioVision 4.8 software. 
Images were processed with Image Pro Plus 6.2 (Media 
Cybernetics).
Statistics
Group differences were evaluated by unpaired t-test, 
One-way ANOVA or Two-way ANOVA and post hoc 
tests corrected for multiple comparisons Newman Keuls 
and Bonferroni’s, respectively. Tests for normal distribu-
tion (Kolmogorov–Smirnov test) were performed, and 
in case of significantly different distributions appropri-
ate non-parametric tests were chosen. GraphPad Prism 
(v4.03) was used for all calculations and for the prepara-
tion of graphs.
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Results
To establish the Line 61 mice as suitable model for in vivo 
screening of new PD modulating compounds we ana-
lyzed these transgenic mice for human and murine α-Syn 
expression, neuroinflammation, motor deficits and emo-
tional learning deficits over age.
Human and mouse α‑Syn expression levels in Line 61 mice
Biochemical evaluation of human α-Syn expression lev-
els in the soluble fraction of the hippocampus of Line 
61 mice by MesoScale Discovery platform revealed an 
increasing expression until 6  months of age (Fig.  1a). 
By contrast, in the soluble fraction of the striatum the 
human α-Syn expression levels significantly decreased 
over age (Fig.  1b). In the insoluble fraction of the hip-
pocampus the human α-Syn expression levels were in 
general lower compared to the soluble fraction and the 
increase over age was weaker but still significant (Fig. 1c 
vs. a). The human α-Syn expression levels in the insoluble 
fraction of the striatum were also lower compared to the 
soluble fraction; the levels varied slightly between ages, 
but differences were not significant (Fig. 1d). In total, the 
α-Syn expression levels increased in the hippocampus 
over age while expression in the striatum decreased or 
rather stayed constant.
Parallel analysis of murine α-Syn levels of 2-, 3- and 
6-month old Line 61 mice revealed an increase of murine 
α-Syn levels in the hippocampus compared to non-
transgenic littermates (Fig.  2a), and at the same time a 
decrease of murine α-Syn in the striatum (Fig. 2b) of Line 
61 and also non-transgenic littermates over age. Interest-
ingly, murine α-Syn protein levels of Line 61 mice were in 
both brain regions slightly lower than in non-transgenic 
littermates (Fig. 2a, b).
Morphological alterations
Immunofluorescent labeling of Line 61 brain tissues 
revealed an overall normal morphology of the brain 
(Fig.  3A). In the hippocampal CA1 region high human 
α-Syn levels in a subset of pyramidal cell somata could be 
observed and most of these show immunoreactivity for 
phosphorylated pSer129-α-Syn (Fig.  3B, C). No obvious 
neuronal loss (Fig. 3D, E) or changes in myelination could 
be detected in 9-month old animals (Fig. 3F–I).
Neuroinflammation
Histological analysis of Line 61 cortical and hippocam-
pal tissue for neuroinflammation revealed a physiologi-
cal pattern of astrocytes and microglia in the adult brain 
without any indication of white matter pathology (Fig. 4). 
Quantification of GFAP and IBA1-immunofluorescence 
in the cortex and hippocampus of 6 and 9  months old 
animals revealed no significant alterations in astrogliosis 
or activated microglia levels in Line 61 mice compared to 
non-transgenic littermates (Fig. 5a–d). In the cortex and 
hippocampus an age dependent increase of astrogliosis 
could be observed in non-transgenic and weaker also in 
Line 61 mice (Fig. 5a, b).
Motor performance of Line 61 mice
Already at 1 month of age Line 61 mice exhibited a sig-
nificantly reduced hanging time in the wire hanging test 
compared to non-transgenic littermates. These deficits 
even increased over age while the performance of non-
transgenic littermates remained unchanged (Fig.  6a). 
Additionally, evaluation of Line 61 mice using the 
RotaRod test revealed first motor deficits as measured 
by latencies to fall from the rod at an age of 2  months 
(Fig. 6b). These differences increased from 1 to 2 months 
of age while deteriorating in adult animals due to an ini-
tially better and later poorer performance of non-trans-
genic littermates (Fig. 6b). To further characterize motor 
deficits in Line 61 mice, the animal’s biting performance 
was tested using the pasta gnawing test, which was 
adapted from [14]. The sound that is produced while eat-
ing a dry spaghetti noodle was recorded and the biting 
peaks per eating episode were measured. The test showed 
that starting at 3  months of age Line 61 mice eat pasta 
Table 1 List of primary antibodies used for histological evaluations
Species Antigen Clone Source Item # Dilution
Rat Human α‑synuclein 15G7 Enzo Life Sciences, Plymouth Meeting, PA 804‑258‑L001 1:10
Rabbit Phospho‑Ser129 α‑synuclein EP1536Y Abcam, Cambridge, UK ab51253 1:2000
Goat Pan synuclein (human and murine α/β/γ‑synuclein) poly Santa Cruz Biotechnology, CA sc‑7012 1:200
Mouse NeuN A60 EMD Millipore, Temecula, CA MAB377 1:500
Rabbit GFAP poly Dako Z0334 1:500
Rat CD11b 5C6 BioRad Laboratories/AbD Serotec MCA711 1:1000
Rabbit IBA1 poly Proteintech 10904‑1‑AP 1:200
Mouse CNPase 11‑5B EMD millipore MAB326 1:250
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with a significantly lower number of peaks per episode 
compared to non-transgenic littermates (Fig. 6c). Neither 
in Line 61 mice nor in non-transgenic littermates did the 
number of biting peaks per episode alter over age. In the 
nest building test first significant differences between 
genotypes were observed at the age of 1 month. At this 
age, Line 61 built poorer nests compared to non-trans-
genic littermates (Fig.  6d). The analysis of nest building 
over age showed that Line 61 animals built nests of the 
same low quality, independent of age, while the nest qual-
ity of non-transgenic littermates significantly increased 
over age, thus increasing the differences between the gen-
otypes with increasing age (Fig. 6d). To corroborate the 
results of these motor tests, 6 months old animals were 
also tested in the beam walk test by using two different 
beams. Analyses of the total number of slips in Line 61 
mice compared to control animals confirmed the motor 
deficits observed in younger animals (Fig. 7a, c). The total 
Fig. 1 Human α‑synuclein protein expression levels in Line 61 mice. Human α‑Syn protein expression levels in the soluble (a, b) and insoluble (c, d) 
fraction of the hippocampus (a, c) and striatum (b, d) of 2‑, 3‑, and 6‑months old Line 61 mice as measured by MesoScale Discovery. n = 5–11 per 
group. Mean ± SEM. One‑way ANOVA followed by Newman’s Keuls posthoc test. *p < 0.05; **p < 0.01; ***p < 0.001
Fig. 2 Murine α‑synuclein protein expression levels in Line 61 mice. Murine α‑Syn protein expression levels in the hippocampus (a) and striatum 
(b) of 2‑, 3‑, and 6‑months old Line 61 and ntg mice as measured by MesoScale Discovery. n = 5–12 per group. Mean ± SEM. Two‑way ANOVA fol‑
lowed by Bonferroni’s posthoc test. *differences between genotypes of the same age, #differences between age groups of one genotype. *p < 0.05; 
**p < 0.01; ***p < 0.001
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time animals needed to perform the test did not change 
in the beam walk test (Fig. 7b, d).
Learning deficits in Line 61 mice
Since PD is not only characterized by motor deficits but 
often also by subcortical dementia, Line 61 mice were 
tested for emotional learning deficits in the contextual 
fear conditioning task. Our results show that at an age of 
8 months Line 61 mice showed less freezing behavior in 
the fear conditioning task compared to non-transgenic 
littermates (Fig.  8) indicating that Line 61 present with 
learning deficits, a symptom rarely observed in other PD 
mouse models. Younger animals of 2, 3 and 6  months 
were also analyzed using the Fear conditioning test, but 
results did not show any significant differences com-
pared to non-transgenic littermates, although a trend 
towards disturbed learning behavior could be observed 
in 6-month old animals (Fig. 8).
Discussion
The Line 61 mouse model represents the highest 
expresser of five published founder lines, with a ten-
fold increased expression of human α-syn compared to 
human control tissue [8]. The original publication pre-
senting this transgenic mouse model provided encourag-
ing data about the expression profile of the human α-Syn 
Fig. 3 Expression of synuclein in Line 61 mice. A A representative section shows expression of transgenic human α‑Syn in a male Line 61 mouse at 
9 months of age. The transgene is ubiquitously present in gray matter with very high expression levels in the isocortex (red channel). B, C Magnified 
single channel images of the hippocampal CA1 region show high human α‑Syn levels in a subset of pyramidal cell somata (arrows, B), and most 
of these show immunoreactivity for phosphorylated pSer129‑α‑Syn (C). D, E The overall morphology of the brain is normal, without any obvious 
occurrence of cell loss in CA1 (NeuN green; DAPI blue). F–I Immunofluorescent labeling in 7‑months old Line 61 mice for total Syn using a pan‑
specific antibody (α/β/γ‑Syn, murine and human), myelinated axons (CNPase green), and DAPI. CX cortex, CPu corpus putamen, HC hippocampus, sl 
stratum lucidum, so stratum oriens, sp stratum pyramidale, sr stratum radiatum. Scale bar A 500 µm; F, H 1000 µm; B–E, G, I 50 µm
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transgene and corresponding α-Syn accumulations in the 
substantia nigra, laying the cornerstone for the success-
ful introduction of a new and promising mouse model for 
PD [8]. Here we analyzed human α-Syn protein expres-
sion levels over age showing a significant increase in the 
soluble and insoluble fraction of the hippocampus up 
to an age of 6 months. The employed Thy-1 promoter is 
known to be inactive until birth but is rapidly increasing 
expression to almost 100-fold during early postnatal 
development [18]. This prompt activation of the pro-
moter can explain why the transgene is already strongly 
up-regulated in 2-month old Line 61 mice. In the solu-
ble and insoluble fraction of the striatum we observed a 
significant decrease or rather no altered expression over 
age of human α-Syn protein expression levels, contrary 
to values in the hippocampus. These data are surprising 
Fig. 4 Expression of glia markers in Line 61 and wild type mice. Immunofluorescent labeling patterns of neuroinflammation markers in 6 and 
9‑months old mice. Magnified single channel images show human α‑Syn immunoreactivity (red channel; note absence of signal in wild type mice), 
IBA1 (microglia white), GFAP (astrocytes green), and DAPI (blue). The general labeling pattern of the gliosis markers is similar in either genotype. CX 
cortex, HC hippocampus, sl stratum lucidum, so stratum oriens, sp stratum pyramidale, sr stratum radiatum. Scale bar A, F, K, P 500 µm; grey images: 
50 µm
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given the significant motor deficits in five different motor 
tests suggesting that the concentration of human α-Syn 
protein in the striatum is not positively associated with 
the corresponding motor or cognitive deficit. Addition-
ally, we observed lower murine α-Syn protein levels in 
Line 61 mice compared to non-transgenic mice, suggest-
ing that over-expression of human α-Syn causes a down-
regulation of endogenous α-Syn.
Our histological analyses revealed that 6 and 9-months 
old Line 61 mice present physiological astrogliosis and 
activated microglia levels in the cortex and hippocam-
pus that slightly increase over age similar to non-trans-
genic littermates. These data contradict results by others 
who provide first evidence of neuroinflammation in this 
mouse model by approximately 9  months [19, 20]. In 
these publications, different antibodies to label GFAP 
were used and the analyzed cortical regions might vary, 
so differences could be caused by systematic differ-
ences and it cannot be excluded that analysis of even 
older animals would reveal an increase in neuroinflam-
matory marker. Animals used for the here presented 
study are genetically separated from the original mouse 
model [8] for already more than 10  years, thus genetic 
differences between the analyzed mice might also have 
caused the observed difference in neuroinflammation. 
In PD patients, neuroinflammation is a common neu-
ropathological feature that is discussed to be induced 
by aggregeted α-Syn but also be able to modulate α-Syn 
processing and clearance [21]. Recent research suggests 
that mutated α-Syn promotes microglia activation much 
stronger than wildtype α-Syn [22]. The physiological 
neuroinflammation levels in Line 61 mice up to an age 
of 9  months suggest that induction of neuroinflamma-
tion by wildtype human α-Syn is not a prerequisite and 
Fig. 5 Quantification of neuroinflammation in 6 and 9‑months old Line 61 mice. Quantification of astroglia (a, b) and activated microglia (c, d) by 
measurement of GFAP and IBA1 suprathreshold area in percent of area of interest in the cortex (a, c) and hippocampus (b, d) of 6 and 9 months 
old Line 61 mice compared to non‑transgenic littermates. n = 6–8 per group. Mean + SEM; One‑way ANOVA followed by Bonferroni’s posthoc test; 
*p < 0.05; **p < 0.01
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neuroinflammatory events in PD might thus not fully 
depend on α-Syn.
Previous reports about Line 61 mice provided first 
proof of motor deficits in Line 61 mice as early as 
2  months of age [11, 12, 23]. Due to the early onset of 
motor deficits, the Line 61 mice were already used to 
study the effect of different compounds, like paraquat 
and dopamine agonists on α-Syn [23, 24]. Here we ana-
lyzed the Line 61 mice for motor deficits in a whole 
series of motor tests and were able to validate previous 
results of other laboratories; in addition we demonstrate 
first motor deficits in 1-month old Line 61 animals that 
worsen over age [11, 12, 23, 24]. The differences between 
Line 61 and non-transgenic littermates in the wire hang-
ing test are already significant at an age of 1 month and 
thus could be used to distinguish transgenic from non-
transgenic mice. This test provides strong evidence for 
the pathological impact of the human α-Syn protein, 
since the expression, regulated by the Thy-1 promoter, 
starts only after birth [12] and still causes severe motor 
changes already at the age of 1  month. Classically, the 
nest building test assesses maternal or social behav-
ior. However, to perform the test properly, motor abili-
ties like orofacial and forelimb movements are essential 
[25], activities that are all dopamine-dependent [26] and 
already shown to be dysfunctional in the striatum of Line 
61 mice [27–30]. The nest building test can therefore 
also be considered as a test for motor skills, supporting 
results from basic motor tests like the bin cotton use [11] 
and the pasta gnawing test in our study. In combination 
with the results of the bin cotton test it is likely that the 
observed nest building deficits are exclusively caused by 
motor shortfalls since the analysis over age shows that 
nest building improves only in older non-transgenic 
mice. Whether Line 61 mice also present maternal or 
social discrepancies remains unclear. The pasta gnaw-
ing test analyzes the gnawing speed and thus a very 
basic motor skill relevant for the primary need of food 
manipulation [15]. First significant differences could be 
observed at the age of 3  months, hence 2  months later 
Fig. 6 Progressive motor deficits of Line 61 mice measured by four different motor tests. a Time in seconds mice hang on the wire in the wire 
hanging test. b Latency to fall from the rotating rod in the RotaRod test. c Peaks per gnawing episode in the pasta gnawing test. d Scoring of the 
nest building test (1 bad nest, 5 perfect nest). a–d n = 10–15 per group; Mean ± SEM. Two‑way ANOVA followed by Bonferroni’s posthoc test. b, c 1 
outlier excluded. *differences between transgenes. #differences between age groups of one genotype. *p < 0.05; **p < 0.01; ***p < 0.001
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as in the wire hanging test. These results suggest that the 
changes observed with the diverse tests depend on dif-
ferent brain regions that are differently affected by the 
α-Syn pathology.
The results of the emotional learning test suggest that 
Line 61 mice present amygdala dependent emotional 
learning deficits as proven with the contextual fear con-
ditioning test and therefore portray similar deficits as 
observed in patients with subcortical dementia but with-
out cortical pathology. Since PD in humans is not only 
characterized by motor deficits like rigor, bradykinesia, 
tremor and postural instability but also by non-motor 
symptoms like hyposmia, gastrointestinal dysfunction, 
anxiety and cognitive decline [31] proper animal mod-
els for PD should also present as many of these non-
motor deficits as possible [32]. It has been previously 
observed that Line 61 mice show olfactory impairments 
at an age of 5–6 months [33] as well as altered basal and 
Fig. 7 Motor deficits of 6‑months old Line 61 mice as measured by Beam walk test. Number of total slips (a, c) and total time in seconds (b, d) that 
Line 61 mice need to traverse the square 10 mm beam (a, b) or the round 16 mm beam (c, d) compared to non‑transgenic littermates. n = 8 per 
group. Mean ± SEM, unpaired t‑test; ***p < 0.001
Fig. 8 Cognitive deficits of Line 61 mice as measured by the fear 
conditioning test. Freezing time of 2, 3, 6, and 8‑months old Line 61 
mice in the fear conditioning test compared to non‑transgenic lit‑
termates. n = 18 per group. Mean ± SEM, unpaired t‑test. **p < 0.01. 
Analysis by two‑way ANOVA resulted in no significant differences
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stress-induced propulsive colonic motility at an age of 
12  months [34]. Together with the data in the present 
study on motor and emotional learning deficits of Line 
61 mice, this transgenic mouse model is not only excel-
lently applicable for the analysis of typical motor deficits 
but also for non-motor discrepancies that are typical for 
PD.
Conclusion
In summary, our data show for the first time progres-
sive motor deficits of Line 61 mice that can already be 
observed at an age of 1 month. The results are in agree-
ment with earlier results of Line 61 mice and emphasize 
the use of this model to test new compounds against PD 
and other synucleinopathies.
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